scholarly journals Collaborative care for major depressive disorder in an occupational healthcare setting

2012 ◽  
Vol 200 (6) ◽  
pp. 510-511 ◽  
Author(s):  
M. C. Vlasveld ◽  
C. M. van der Feltz-Cornelis ◽  
H. J. Adèr ◽  
J. R. Anema ◽  
R. Hoedeman ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Collaborative Care ◽  
Outcome Measure ◽  
Controlled Trial ◽  
Healthcare Setting ◽  
Primary Outcome Measure ◽  
Major Depressive ◽  
Randomised Controlled ◽  
Occupational Healthcare

SummaryRandomised controlled trial to evaluate the effectiveness of collaborative care in a Dutch occupational healthcare setting: 126 workers on sick leave with major depressive disorder were randomised to usual care (n = 61) or collaborative care (n = 65). After 3 months, collaborative care was more effective on the primary outcome measure of treatment response (i.e. reduction in symptoms of ≥50%) on the Patient Health Questionnaire-9 (PHQ-9). However, the groups did not differ on the PHQ-9 as a continuous outcome measure. Implications of these results are discussed.

Acute and one-year outcome of a randomised controlled trial of brief cognitive therapy for major depressive disorder in primary care

1997 ◽  
Vol 171 (2) ◽  
pp. 131-134 ◽  
Author(s):  
Christine Scott ◽  
Mary Jane Tacchi ◽  
Roger Jones ◽  
Jan Scott
Keyword(s):  
Primary Care ◽  
Major Depressive Disorder ◽  
Randomised Controlled Trial ◽  
Depressive Disorder ◽  
Cognitive Therapy ◽  
Controlled Trial ◽  
Control Group ◽  
Major Depressive ◽  
Treatment As Usual ◽  
Randomised Controlled

BackgroundThe consensus statement on the treatment of depression (Paykel & Priest, 1992) advocates the use of cognitive therapy techniques as an adjunct to medication.MethodThis paper describes a randomised controlled trial of brief cognitive therapy (BCT) plus ‘treatment as usual’ versus treatment as usual in the management of 48 patients with major depressive disorder presenting in primary care.ResultsAt the end of the acute phase, significantly more subjects (P < 0.05) met recovery criteria in the intervention group (n=15) compared with the control group (n=8). When initial neuroticism scores were controlled for, reductions in Beck Depression Inventory and Hamilton Rating Scale for Depression scores favoured the BCT group throughout the 12 months of follow-up.ConclusionsBCT may be beneficial, but given the time constraints, therapists need to be more rather than less skilled in cognitive therapy. This, plus methodological limitations, leads us to advise caution before applying this approach more widely in primary care.

scholarly journals Psilocybin-assisted therapy for the treatment of resistant major depressive disorder (PsiDeR): protocol for a randomised, placebo-controlled feasibility trial

BMJ Open ◽  
2021 ◽  
Vol 11 (12) ◽  
pp. e056091
Author(s):  
James Rucker ◽  
Hassan Jafari ◽  
Tim Mantingh ◽  
Catherine Bird ◽  
Nadav Liam Modlin ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Informed Consent ◽  
Depressive Disorder ◽  
Primary Outcome ◽  
Rating Scale ◽  
Outcome Measure ◽  
Primary Outcome Measure ◽  
Feasibility Trial ◽  
Open Label ◽  
Major Depressive

IntroductionPsilocybin-assisted therapy may be a new treatment for major depressive disorder (MDD), with encouraging data from pilot trials. In this trial (short name: PsiDeR) we aimed to test the feasibility of a parallel-group, randomised, placebo-controlled design. The primary outcomes in this trial are measures of feasibility: recruitment rates, dropout rates and the variance of the primary outcome measure of depression.Methods and analysisWe are recruiting up to 60 participants at a single centre in London, UK who are unresponsive to, or intolerant of, at least two evidence-based treatments for MDD. Participants are randomised to receive a single dosing session of 25 mg psilocybin or a placebo. All participants receive a package of psychological therapy. The primary outcome measure for depression is the Montgomery Asberg Depression Rating Scale collected by blinded, independent raters. The primary endpoint is at 3 weeks, and the total follow-up is 6 weeks. With further informed consent, this study collects neuroimaging and omics data for mechanism and biomarker analyses and offers participants an open label extension consisting of a further, open label dose of 25 mg of psilocybin.Ethics and disseminationAll participants will be required to provide written informed consent. The trial has been authorised by the National Research Ethics Committee (20-LO/0206), Health Research Authority (252750) and Medicine’s and Healthcare Products Regulatory Agency (CTA 14523/0284/001-0001) in the UK. Dissemination of results will occur via a peer-reviewed publication and other relevant media.Trial registration numbersEUDRACT2018-003573-97; NCT04959253.

Sign in / Sign up

Export Citation Format

Share Document